Research Article| Volume 151, ISSUE 3, P477-480, December 2018

Download started.


Patients with BRCA mutations have superior outcomes after intraperitoneal chemotherapy in optimally resected high grade ovarian cancer

Published:October 08, 2018DOI:


      • BRCA+ patients identified by genetic sequencing have superior outcomes compared to BRCA - patients when treated with IP chemotherapy.
      • BRCA mutated patients may be a group that would benefit most from IP chemotherapy.
      • The benefit for BRCA mutated patients were seen at doses of cisplatin lower than those used in GOG 172.



      To compare the outcomes after intraperitoneal (IP) chemotherapy in patients with and without pathogenic BRCA mutations.


      Patients with high grade ovarian cancer who were treated with adjuvant IP chemotherapy in the initial setting between 2005 and 2016 were identified. Outcomes were compared between patients with pathogenic mutations in BRCA (BRCA+) and those who tested negative or were unknown (BRCA−).


      A total of 100 eligible patients were identified. The median follow-up was 47.0 months (range, 6.6–144.1 months). Of these 100 patients, 77 patients underwent BRCA testing; 25 patients (32%) were BRCA+ (23 germline, 2 somatic). No differences were noted between groups with respect to number of IP cycles, stage, or residual disease after surgery. The median progression-free survival (PFS) was longer in the BRCA+ group; median PFS was not reached in the BRCA+ group compared to 17.3 months in the BRCA− group (HR = 0.38; 95% CI 0.20–0.73, P = 0.003). Median overall survival (OS) was longer in the BRCA+ group at 110.4 months versus 67.1 months (HR = 0.28, 95% CI 0.11–0.73, P = 0.009).


      Pathogenic BRCA mutations are more common than expected in optimally resected ovarian cancer patients selected for IP therapy. IP therapy was associated with a dramatic improvement in PFS and OS in BRCA+ patients compared with BRCA− patients. This improvement is greater than has been reported for BRCA+ patients with IV chemotherapy. The magnitude of this benefit suggests that patients with pathogenic mutations in BRCA may benefit from IP therapy.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2016.
        CA Cancer J. Clin. 2016; 66: 7-30
        • McGuire W.P.
        • Hoskins W.J.
        • Brady M.F.
        • Kucera P.R.
        • Partridge E.E.
        • Look K.Y.
        • et al.
        Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
        N. Engl. J. Med. 1996; 334: 1-6
        • Miller K.D.
        • Siegel R.L.
        • Lin C.C.
        • Mariotto A.B.
        • Kramer J.L.
        • Rowland J.H.
        • et al.
        Cancer treatment and survivorship statistics, 2016.
        CA Cancer J. Clin. 2016; 66: 271-289
        • Alberts D.S.
        • Liu P.Y.
        • Hannigan E.V.
        • O'Toole R.
        • Williams S.D.
        • Young J.A.
        • et al.
        Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.
        N. Engl. J. Med. 1996; 335: 1950-1955
        • Markman M.
        • Bundy B.N.
        • Alberts D.S.
        • Fowler J.M.
        • Clark-Pearson D.L.
        • Carson L.F.
        • et al.
        Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.
        J. Clin. Oncol. 2001; 19: 1001-1007
        • Armstrong D.K.
        • Bundy B.
        • Wenzel L.
        • Huang H.Q.
        • Baergen R.
        • Lele S.
        • et al.
        Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
        N. Engl. J. Med. 2006; 354: 34-43
        • Trimble E.L.
        • Christian M.C.
        National Cancer Institute-United States strategy regarding intraperitoneal chemotherapy for ovarian cancer.
        Int. J. Gynecol. Cancer. 2008; 18: 26-28
        • Naumann R.W.
        • Sukumvanich P.
        • Edwards R.P.
        Practice patterns of intraperitoneal chemotherapy in women with ovarian cancer.
        Gynecol. Oncol. 2009; 114: 37-41
        • Walker J.L.
        Intraperitoneal chemotherapy for ovarian cancer.
        Gynecol. Oncol. 2016; 142: 1-2
        • Lesnock J.L.
        • Darcy K.M.
        • Tian C.
        • Deloia J.A.
        • Thrall M.M.
        • Zahn C.
        • et al.
        BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.
        Br. J. Cancer. 2013; 108: 1231-1237
        • Kaplan E.L.
        • Meier P.
        Nonparametric estimation from incomplete observations.
        J. Am. Stat. Assoc. 1958; 53: 457-481
        • Bolton K.L.
        • Chenevix-Trench G.
        • Goh C.
        • Sadetzki S.
        • Ramus S.J.
        • Karlan B.Y.
        • et al.
        Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.
        JAMA. 2012; 307: 382-390
        • Sun C.
        • Li N.
        • Ding D.
        • Weng D.
        • Meng L.
        • Chen G.
        • et al.
        The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis.
        PLoS One. 2014; 9e95285
        • Hasovits C.
        • Clarke S.
        Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics.
        Clin. Pharmacokinet. 2012; 51: 203-224
        • Alberts D.S.
        • Hannigan E.V.
        • Liu P.Y.
        • Jiang C.
        • Wilczynski S.
        • Copeland L.
        • et al.
        Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: an intergroup study.
        Gynecol. Oncol. 2006; 100: 133-138
        • Wright A.A.
        • Cronin A.
        • Milne D.E.
        • Bookman M.A.
        • Burger R.A.
        • Cohn D.E.
        • et al.
        Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancer.
        J. Clin. Oncol. 2015; 33: 2841-2847
        • Walker J.
        • Brady M.F.
        • DiSilvestro P.A.
        • Fujiwara K.
        • Alberts D.
        • Zheng W.
        • et al.
        A phase III trial of bevacizumab with IV versus IP chemotherapy for ovarian, fallopian tube, and peritoneal carcinoma: an NRG Oncology Study.
        Gynecol. Oncol. 2016; 141: 208
        • van Driel W.J.
        • Koole S.N.
        • Sonke G.S.
        Hyperthermic intraperitoneal chemotherapy in ovarian cancer.
        N. Engl. J. Med. 2018; 378: 1363-1364